Hepatitis E virus infection

Nassim Kamar, Jacques Izopet, Nicole Pavio, Rakesh Aggarwal, Alain B Labrique, Heiner Wedemeyer, Harry R. Dalton

Research output: Contribution to journalReview article

Abstract

Hepatitis E virus (HEV) infection can lead to acute and chronic hepatitis as well as to extrahepatic manifestations such as neurological and renal disease; it is the most common cause of acute viral hepatitis worldwide. Four genotypes are responsible for most infection in humans, of which HEV genotypes 1 and 2 are obligate human pathogens and HEV genotypes 3 and 4 are mostly zoonotic. Until quite recently, HEV was considered to be mainly responsible for epidemics of acute hepatitis in developing regions owing to contamination of drinking water supplies with human faeces. However, HEV is increasingly being recognized as endemic in some developed regions. In this setting, infections occur through zoonotic transmission or contaminated blood products and can cause chronic hepatitis in immunocompromised individuals. HEV infections can be diagnosed by measuring anti-HEV antibodies, HEV RNA or viral capsid antigen in blood or stool. Although an effective HEV vaccine exists, it is only licensed for use in China. Acute hepatitis E is usually self-limiting and does not require specific treatment. Management of immunocompromised individuals involves lowering the dose of immunosuppressive drugs and/or treatment with the antiviral agent ribavirin.

Original languageEnglish (US)
Article number17086
JournalNature Reviews Disease Primers
Volume3
DOIs
StatePublished - Nov 16 2017

Fingerprint

Hepatitis E virus
Virus Diseases
Genotype
Zoonoses
Chronic Hepatitis
Hepatitis
Hepatitis E
Viral Antigens
Water Supply
Ribavirin
Capsid
Immunosuppressive Agents
Infection
Feces
Drinking Water
Antiviral Agents
China
Vaccines
RNA
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kamar, N., Izopet, J., Pavio, N., Aggarwal, R., Labrique, A. B., Wedemeyer, H., & Dalton, H. R. (2017). Hepatitis E virus infection. Nature Reviews Disease Primers, 3, [17086]. https://doi.org/10.1038/nrdp.2017.86

Hepatitis E virus infection. / Kamar, Nassim; Izopet, Jacques; Pavio, Nicole; Aggarwal, Rakesh; Labrique, Alain B; Wedemeyer, Heiner; Dalton, Harry R.

In: Nature Reviews Disease Primers, Vol. 3, 17086, 16.11.2017.

Research output: Contribution to journalReview article

Kamar, N, Izopet, J, Pavio, N, Aggarwal, R, Labrique, AB, Wedemeyer, H & Dalton, HR 2017, 'Hepatitis E virus infection', Nature Reviews Disease Primers, vol. 3, 17086. https://doi.org/10.1038/nrdp.2017.86
Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique AB, Wedemeyer H et al. Hepatitis E virus infection. Nature Reviews Disease Primers. 2017 Nov 16;3. 17086. https://doi.org/10.1038/nrdp.2017.86
Kamar, Nassim ; Izopet, Jacques ; Pavio, Nicole ; Aggarwal, Rakesh ; Labrique, Alain B ; Wedemeyer, Heiner ; Dalton, Harry R. / Hepatitis E virus infection. In: Nature Reviews Disease Primers. 2017 ; Vol. 3.
@article{aa4c95665c0f4e9da5a9bd401243927d,
title = "Hepatitis E virus infection",
abstract = "Hepatitis E virus (HEV) infection can lead to acute and chronic hepatitis as well as to extrahepatic manifestations such as neurological and renal disease; it is the most common cause of acute viral hepatitis worldwide. Four genotypes are responsible for most infection in humans, of which HEV genotypes 1 and 2 are obligate human pathogens and HEV genotypes 3 and 4 are mostly zoonotic. Until quite recently, HEV was considered to be mainly responsible for epidemics of acute hepatitis in developing regions owing to contamination of drinking water supplies with human faeces. However, HEV is increasingly being recognized as endemic in some developed regions. In this setting, infections occur through zoonotic transmission or contaminated blood products and can cause chronic hepatitis in immunocompromised individuals. HEV infections can be diagnosed by measuring anti-HEV antibodies, HEV RNA or viral capsid antigen in blood or stool. Although an effective HEV vaccine exists, it is only licensed for use in China. Acute hepatitis E is usually self-limiting and does not require specific treatment. Management of immunocompromised individuals involves lowering the dose of immunosuppressive drugs and/or treatment with the antiviral agent ribavirin.",
author = "Nassim Kamar and Jacques Izopet and Nicole Pavio and Rakesh Aggarwal and Labrique, {Alain B} and Heiner Wedemeyer and Dalton, {Harry R.}",
year = "2017",
month = "11",
day = "16",
doi = "10.1038/nrdp.2017.86",
language = "English (US)",
volume = "3",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Hepatitis E virus infection

AU - Kamar, Nassim

AU - Izopet, Jacques

AU - Pavio, Nicole

AU - Aggarwal, Rakesh

AU - Labrique, Alain B

AU - Wedemeyer, Heiner

AU - Dalton, Harry R.

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Hepatitis E virus (HEV) infection can lead to acute and chronic hepatitis as well as to extrahepatic manifestations such as neurological and renal disease; it is the most common cause of acute viral hepatitis worldwide. Four genotypes are responsible for most infection in humans, of which HEV genotypes 1 and 2 are obligate human pathogens and HEV genotypes 3 and 4 are mostly zoonotic. Until quite recently, HEV was considered to be mainly responsible for epidemics of acute hepatitis in developing regions owing to contamination of drinking water supplies with human faeces. However, HEV is increasingly being recognized as endemic in some developed regions. In this setting, infections occur through zoonotic transmission or contaminated blood products and can cause chronic hepatitis in immunocompromised individuals. HEV infections can be diagnosed by measuring anti-HEV antibodies, HEV RNA or viral capsid antigen in blood or stool. Although an effective HEV vaccine exists, it is only licensed for use in China. Acute hepatitis E is usually self-limiting and does not require specific treatment. Management of immunocompromised individuals involves lowering the dose of immunosuppressive drugs and/or treatment with the antiviral agent ribavirin.

AB - Hepatitis E virus (HEV) infection can lead to acute and chronic hepatitis as well as to extrahepatic manifestations such as neurological and renal disease; it is the most common cause of acute viral hepatitis worldwide. Four genotypes are responsible for most infection in humans, of which HEV genotypes 1 and 2 are obligate human pathogens and HEV genotypes 3 and 4 are mostly zoonotic. Until quite recently, HEV was considered to be mainly responsible for epidemics of acute hepatitis in developing regions owing to contamination of drinking water supplies with human faeces. However, HEV is increasingly being recognized as endemic in some developed regions. In this setting, infections occur through zoonotic transmission or contaminated blood products and can cause chronic hepatitis in immunocompromised individuals. HEV infections can be diagnosed by measuring anti-HEV antibodies, HEV RNA or viral capsid antigen in blood or stool. Although an effective HEV vaccine exists, it is only licensed for use in China. Acute hepatitis E is usually self-limiting and does not require specific treatment. Management of immunocompromised individuals involves lowering the dose of immunosuppressive drugs and/or treatment with the antiviral agent ribavirin.

UR - http://www.scopus.com/inward/record.url?scp=85034838890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034838890&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2017.86

DO - 10.1038/nrdp.2017.86

M3 - Review article

C2 - 29154369

AN - SCOPUS:85034838890

VL - 3

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 17086

ER -